(Q35675197)

9 August 2017

1 reference

title

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies (English)

1 reference

9 August 2017

0 references

1 reference

4

Theresa A Guise

1 reference

9 August 2017

2

Celestia S Higano

1 reference

9 August 2017

Terrence H Diamond

1

1 reference

9 August 2017

Matthew R Smith

series ordinal

3

1 reference

9 August 2017

Frederick R Singer

series ordinal

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

100

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

892-899

1 reference

Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Fracture risk following bilateral orchiectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bone density and fracture risk in men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bone densitometry: choosing the proper skeletal site to measure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Background for studies on the treatment of male osteoporosis: state of the art.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

What is the role of serial bone mineral density measurements in patient management?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Hip fracture prediction in elderly men and women: validation in the Rotterdam study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Global public health and the information superhighway. Doctors and students need computer training

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Men, bone and estrogen: unresolved issues.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

The crippling consequences of fractures and their impact on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Pathogenesis of vertebral crush fractures in men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Gender specificity in the genetic determinants of peak bone mass

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bisphosphonates in the treatment of bone diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20056

7 January 2021

Identifiers

DOI

10.1002/CNCR.20056

1 reference

9 August 2017

1 reference